More companies sign up to open innovation
This article was originally published in Scrip
Executive Summary
Last week, Virttu Biologics, a clinical-stage biotechnology company based in Scotland, launched a new R&D network for the development of novel oncology combination therapies. The company focuses on new treatments based on oncolytic viruses, and the new Virttu Replicate Open Innovation Forum, which is open to researchers in academia as well as in biopharmaceutical companies, is intended to stimulate the development of new combination therapies by providing access to Virttu’s Seprehvir oncolytic virus.